WHO ICTRP trial
A randomized placebo-controlled clinical study of the efficacy and safety of…
ChiCTR2400090156 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400090156 |
|---|---|
| Public title | A randomized placebo-controlled clinical study of the efficacy and safety of Tanshinone capsules in the treatment of COVID-19 |
| Scientific title | A randomized placebo-controlled clinical study of the efficacy and safety of Tanshinone capsules in the treatment of COVID-19 |
| Primary sponsor | Dongguan People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Novel Coronavirus Pneumonia (COVID-19) |
| Interventions | Experimental group:Symptomatic treatment + Tanshinone capsules (oral, 4 capsules/time, 3 times/day), 5 days of treatment (compliance);Control group:Symptomatic treatment + Tanshinone capsule placebo (oral, 4 / time, 3 times/day), the course… |
| Registration date | Sep 25, 2024 |
| Target size | Experimental group:80;Control group:80 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: